Brokerages forecast that DENTSPLY SIRONA Inc (NASDAQ:XRAY) will report earnings per share (EPS) of $0.62 for the current quarter, Zacks reports. Seven analysts have issued estimates for DENTSPLY SIRONA’s earnings, with the lowest EPS estimate coming in at $0.57 and the highest estimate coming in at $0.66. DENTSPLY SIRONA posted earnings per share of $0.60 in the same quarter last year, which indicates a positive year over year growth rate of 3.3%. The company is expected to issue its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that DENTSPLY SIRONA will report full year earnings of $2.34 per share for the current financial year, with EPS estimates ranging from $2.31 to $2.37. For the next fiscal year, analysts forecast that the company will post earnings of $2.64 per share, with EPS estimates ranging from $2.52 to $2.75. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. The company had revenue of $946.20 million for the quarter, compared to analyst estimates of $925.13 million. DENTSPLY SIRONA had a positive return on equity of 8.99% and a negative net margin of 26.48%. The business’s revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 earnings per share.

XRAY has been the subject of a number of recent analyst reports. HC Wainwright set a $49.00 price objective on DENTSPLY SIRONA and gave the company a “hold” rating in a report on Friday, April 5th. UBS Group began coverage on DENTSPLY SIRONA in a report on Thursday, January 17th. They issued a “neutral” rating and a $42.00 price objective for the company. William Blair raised DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $56.71 target price for the company in a research note on Monday, March 18th. Robert W. Baird boosted their target price on DENTSPLY SIRONA from $42.00 to $50.00 and gave the company a “neutral” rating in a research note on Monday, March 4th. Finally, Bank of America began coverage on DENTSPLY SIRONA in a research note on Monday, March 18th. They issued a “buy” rating and a $57.00 target price for the company. Eight research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $53.65.

XRAY stock opened at $54.87 on Friday. The firm has a market cap of $12.84 billion, a PE ratio of 27.30, a PEG ratio of 2.05 and a beta of 1.11. The company has a quick ratio of 1.27, a current ratio of 2.06 and a debt-to-equity ratio of 0.33. DENTSPLY SIRONA has a twelve month low of $33.93 and a twelve month high of $55.88.

In related news, SVP Daniel P. Key acquired 3,697 shares of the stock in a transaction on Tuesday, May 7th. The shares were purchased at an average price of $54.68 per share, for a total transaction of $202,151.96. Following the purchase, the senior vice president now directly owns 9,024 shares in the company, valued at $493,432.32. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Maureen J. Macinnis sold 54,402 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $55.00, for a total value of $2,992,110.00. Following the transaction, the senior vice president now owns 50,962 shares in the company, valued at approximately $2,802,910. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,022 shares of company stock worth $5,535,985. Corporate insiders own 0.62% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Hanseatic Management Services Inc. acquired a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at $30,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of DENTSPLY SIRONA in the 4th quarter valued at $26,000. Private Capital Group LLC boosted its holdings in shares of DENTSPLY SIRONA by 105.3% in the 4th quarter. Private Capital Group LLC now owns 700 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 359 shares in the last quarter. Pinnacle Bank acquired a new stake in shares of DENTSPLY SIRONA in the 4th quarter valued at $26,000. Finally, Truehand Inc acquired a new stake in shares of DENTSPLY SIRONA in the 4th quarter valued at $27,000. 99.78% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Featured Story: What is the quiet period?

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.